Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

BACKGROUND: A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubicin alone. The recently presented phase III study of doxorubicin and olaratumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gennatas, Spyridon, Chamberlain, Florence, Carter, Thomas, Slater, Susanna, Cojocaru, Elena, Lambourn, Beth, Stansfeld, Anna, Todd, Radha, Verrill, Mark, Ali, Nasim, Jones, Robin L., Simmonds, Peter, Keay, Nicola, McCarty, Heather, Strauss, Sandra, Karavasilis, Vassilios, Dileo, Palma, Benson, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203838/
https://www.ncbi.nlm.nih.gov/pubmed/32391141
http://dx.doi.org/10.1186/s13569-020-00131-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203838/
https://www.ncbi.nlm.nih.gov/pubmed/32391141
http://dx.doi.org/10.1186/s13569-020-00131-x

Ejemplares similares